COO:NYE-Cooper Companies Inc. (The) (USD)

EQUITY | Medical Instruments & Supplies | New York Stock Exchange

Last Closing

USD 97.9

Change

+1.94 (+2.02)%

Market Cap

USD 8.14B

Volume

0.78M

Analyst Target

USD 346.82
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The Cooper Companies Inc is a medical device company. Through its subsidiaries, it manufactures products for contact lens wearers and supplies women's health clinicians with products and treatment options to improve the delivery of healthcare to women.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

-2.54 (-0.49%)

USD 182.57B
HOLX Hologic Inc

+0.32 (+0.40%)

USD 18.90B
ALGN Align Technology Inc

-1.92 (-0.90%)

USD 15.89B
RGEN Repligen Corporation

+1.51 (+1.12%)

USD 8.01B
MMSI Merit Medical Systems Inc

-1.00 (-1.04%)

USD 5.55B
XRAY Dentsply Sirona Inc

+0.18 (+0.77%)

USD 4.87B
ICUI ICU Medical Inc

+0.37 (+0.21%)

USD 4.34B
AZTA Azenta Inc

+0.32 (+0.77%)

USD 2.04B
LMAT LeMaitre Vascular Inc

-1.36 (-1.50%)

USD 1.96B
STAA STAAR Surgical Company

-0.80 (-2.64%)

USD 1.51B

ETFs Containing COO

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.48% 61% D- 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.48% 61% D- 59% D-
Trailing 12 Months  
Capital Gain 1.52% 72% C 49% F
Dividend Return 0.01% 20% F N/A F
Total Return 1.53% 72% C 46% F
Trailing 5 Years  
Capital Gain 33.78% 74% C 68% D+
Dividend Return 0.09% 25% F 1% F
Total Return 33.87% 74% C 65% D
Average Annual (5 Year Horizon)  
Capital Gain 5.74% 57% F 63% D
Dividend Return 5.75% 57% F 59% D-
Total Return 0.02% 17% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 20.48% 93% A 75% C
Risk Adjusted Return 28.08% 64% D 63% D
Market Capitalization 8.14B 98% N/A 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 33.90 41% 16%
Price/Book Ratio 2.42 53% 41%
Price / Cash Flow Ratio 30.98 25% 9%
Price/Free Cash Flow Ratio 23.72 21% 10%
Management Effectiveness  
Return on Equity 3.87% 76% 64%
Return on Invested Capital 4.13% 73% 67%
Return on Assets 2.69% 74% 78%
Debt to Equity Ratio 33.42% 41% 50%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.